Clinical Trial Detail

NCT ID NCT02607228
Title Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GS-5829 as a Single Agent and In Combination With Enzalutamide in Participants With Metastatic Castrate-Resistant Prostate Cancer
Recruitment Completed
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors Gilead Sciences
Indications

prostate cancer

Therapies

Enzalutamide

Exemestane + GS-5829

Age Groups: adult

No variant requirements are available.